Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
Unfinished Business: Understanding Drug Effects on Dopamine Pathways

25 July 2008. Since its discovery 25 years ago by Nobel prize winner Paul Greengard, the phosphatase and kinase inhibitor DARPP-32 (dopamine- and cAMP-regulated protein of 32 kilodaltons) has proven to be a central signaling molecule in the dopamine pathway, and in the action of other neurotransmitters (see SRF related news story and also SRF news story for a perspective on Greengard’s work on the protein). Dopamine signaling is altered in schizophrenia, as are DARPP-32 levels (Albert et al., 2002), and genetic variation in DARPP-32 was recently tied to schizophrenia risk (see SRF related news story). Just how DARPP-32 might figure in producing the symptoms of schizophrenia, however, is unclear.

In a paper in the July 11 issue of Nature Neuroscience, Greengard and colleagues at the Rockefeller University in New York take another step toward unraveling the tangled web of DARPP-32’s actions. They report how two drugs—cocaine, a psychostimulant, and haloperidol, a sedative antipsychotic still being used to treat schizophrenia—that on the surface appear to similarly alter the phosphorylation DARPP-32 in the same brain region, actually target the protein in distinct neuronal subpopulations. The work provides a possible explanation for the diverse behavioral effects of the two agents. Along the way, first author Helen Bateup and colleagues present a powerful approach to studying cell type-specific phosphorylation of proteins and provide a cautionary tale about making biochemical observations on mixed populations of cells.

In other news concerning the mechanism of action of a different type of drug, Randy Blakely and Aurelio Galli of the Vanderbilt University Medical Center in Nashville, Tennessee, report in the July 9 Journal of Neuroscience that a rare, human dopamine transporter (DAT) variant associated with attention-deficit hyperactivity disorder (ADHD) triggers a reversal of the transporter action to cause dopamine efflux from cells. This is intriguing because the “reversal of function” mutant mimics the action of amphetamine, a common ADHD treatment that is thought to raise synaptic dopamine in part by stimulating DAT-mediated dopamine efflux. Surprisingly, amphetamine actually blocks efflux through the mutant proteins, the investigators show. The results suggest that abnormal dopamine efflux could contribute to dopamine signaling disorders, and that blockade of inappropriate efflux could somehow contribute to the therapeutic actions of DAT-targeted stimulants.

The ups and downs of DARPP-32 phosphorylation In the first study, the researchers set out to investigate a paradox: both the psychostimulant cocaine and the sedation-producing antipsychotic haloperidol act on striatal neurons to modulate DARPP-32 phosphorylation, but their behavioral effects are vastly different. It was known that the drugs act on different subpopulations of striatal neurons that make up distinct output pathways (cocaine acts on striatonigral neurons, while haloperidol acts on striatopallidal neurons). To test the hypothesis that the drugs might differentially affect DARPP-32 phosphorylation in the two cell types, the researchers expressed different epitope-tagged versions of DARPP-32 in either striatonigral neurons (using a dopamine type 1 receptor [D1R] promoter) or in striatopallidal neurons (using a dopamine type 2 receptor [D2R]) promoter) in transgenic mice. Then, they used tag-specific immunoprecipitation after treatment of animals with the medications to follow the phosphorylation of DARPP-32 at two critical residues, threonine 34 and 75 (T34 or T75), in both cell types. The method, they write, “allowed a quantitative side by side comparison of phosphorylation events occurring selectively in two distinct neuronal populations in vivo.” Phosphorylation at T34 is important because it activates the phosphatase inhibitory activity of DARPP-32, while modification at T75 makes the protein an activator of protein kinase A.

In this way, the researchers tested the effects of cocaine and haloperidol on DARPP-32 phosphorylation in vivo. Previous work showed that both cocaine and haloperidol increase DARPP-32 phosphorylation at the critical regulatory residue T34 in whole striatum. The transgenic mice confirmed this result, but revealed that the increase actually occurred in different neurons for the two agents. After cocaine treatment, it was the striatonigral neurons that displayed an increase in T34 phosphorylation, while striatopallidal neurons showed a decrease. Phosphorylation at T75 showed reciprocal changes in the opposite direction in each cell type. On the other hand, haloperidol induced an increase in T34 only in striatopallidal neurons, and caused no change at T75.

The researchers tested other psychoactive agents, and found that they, too, had cell type-specific actions. The atypical antipsychotic clozapine acted like haloperidol to increase T34 phosphorylation specifically in striatopallidal neurons, but it had a different effect on T75, where it increased phosphorylation at that residue in both cell types. In addition, caffeine had an opposite effect to haloperidol, acting to increase T75 phosphorylation, consistent with the opposing stimulant and sedative effects of the two agents.

The differential regulation of striatonigral and striatopallidal neurons could explain the drugs’ different behavioral effects, the authors conclude, as the two types of neurons couple to opposing output pathways. “We have resolved the paradox that psychostimulants and antipsychotics cause the same biochemical change in the striatum, but have opposing behavioral and clinical effects,” they write.

The basis for the cell-specific effects are not completely clear. Differential expression of type 1 versus type 2 dopamine receptors on the two cell populations may explain why, for example, the type 2 antagonist haloperidol acts selectively on striatopallidal neurons. The whole story is likely to be more complex, however. In other experiments, the researchers showed that the effects of specific D1R and D2R receptor agonists on DARPP-32 phosphorylation in vivo differed from their effects in isolated striatal slices. Thus, in vivo effects of drugs are likely affected by the presence of intact physiological inputs into the striatum, which allow for a host of secondary actions of dopamine receptor blockade. (The slice experiments also raise the concern that isolated in vitro preparations, often used to study signaling pathways, do not give an accurate readout of drug effects.)

From their results, the authors argue that the regulation of T34 phosphorylation in striatopallidal, dopamine type 2-expressing neurons may represent a common mechanism of action of antipsychotics. In support of this idea, they show that the levels of phosphorylation achieved with haloperidol are much higher than with clozapine, which they speculate may be associated with locomotor side effects. The levels of T34 achieved with clozapine, coupled with its additional effects on T75, may make it more tolerable, they speculate.

“The importance of selectively analyzing responses in these two neuronal populations is becoming increasingly clear, as recent studies have shown substantial difference between D1R- and D2R-expressing striatal neurons with regard to their synaptic properties and regulation of dendritic spine number,” the authors conclude. The investigators show that since the tagged DARPP-32 protein only represents a few percent of total DARPP-32, its presence does not appear to disrupt physiological regulation of phosphorylation, or DARPP-32’s ability to regulate downstream kinase and phosphatase pathways. Thus, the method of expressing cell-targeted epitope-tagged proteins may be generally useful for probing the biochemistry of other cell types, and other protein modifications.

The ins and outs of dopamine The second study focuses on an aberration in dopamine signaling induced by a rare human dopamine transporter (DAT) variant found in two boys with ADHD and a woman with bipolar disorder. The variant, an Ala559Val substitution, has normal dopamine uptake activity, but the researchers, led by first authors Michelle Mazei-Robison and Erica Bowton, found that the mutant leaks dopamine from depolarized cells. This behavior is similar to the effects of amphetamine on dopamine transporters, where the drug not only inhibits dopamine uptake, but also stimulates efflux. The clinical benefits of amphetamine are thought to be due to its ability to increase synaptic dopamine levels and overcome dopamine deficiencies.

Surprisingly, both boys with the effluxing mutant had been treated successfully with amphetamines. This led the researchers to test amphetamine and the other most common ADHD medication, methylphenidate, on the A559V transporter. In both cases, they found the drugs blocked the abnormal efflux. From these results, they speculate that the therapeutic actions of transporter antagonists, “currently attributed to blockage of neurotransmitter reuptake, may in some cases arise from cessation of transporter-mediated neurotransmitter efflux. Our findings argue for further inspection of anomalous transporter-mediated neurotransmitter efflux as an unappreciated source of risk for brain disorders.” Among those diseases could be “disorders that benefit from blockade of DA receptors, such as schizophrenia,” they speculate.—Pat McCaffrey.

References:
Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci. 2008 Jul 11. Abstract

Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD. Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci. 2008 Jul 9;28(28):7040-6. Abstract

 
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


SRF News
SRF Comments
Text Size
Reset Text Size
Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright